3:37 PM
Mar 12, 2018
 |  BC Extra  |  Company News

Management tracks: WuXi NextCode, Assembly

WuXi NextCode Genomics Inc. (Cambridge, Mass.) said CEO Hannes Smárason is stepping down. He is succeeded by EVP and COO Rob Brainin. Last year, the genomics company raised $240 million in a series B round on its path to a potential IPO (see BioCentury Extra, Sept. 7, 2017).

HBV and microbiome company Assembly Biosciences Inc. (NASDAQ:ASMB) said CFO and COO David Barrett is stepping down. He is succeeded by Graham Cooper. Cooper was CFO of Receptos Inc., which Celgene Corp. (NASDAQ:CELG) acquired.

Antibody-drug conjugate (ADC) developer Mersana Therapeutics Inc. (NASDAQ:MRSN) hired David Spellman as CFO. He was VP of corporate, commercial and international finance at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).

Gene expression company Syros Pharmaceuticals Inc. (NASDAQ:SYRS) hired Joseph Ferra as CFO. He was managing director and co-head of healthcare investment banking at JMP Securities.

Hematology company Portola Pharmaceuticals Inc. (NASDAQ:PTLA) hired John Moriarty as EVP and general counsel. He was EVP and general counsel at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN).

Regenerative medicine company Frequency Therapeutics Inc. (Woburn, Mass.) hired Carl LeBel as EVP of clinical development. He was CSO at Otonomy Inc. (NASDAQ:OTIC).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD